Think of Enterprise Value as the theoretical takeover price. It is more comprehensive than market capitalization (Market Cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Bristol-Myers Squibb Co's Enterprise Value is €135,828 Mil.
Bristol-Myers Squibb Co's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 was €9,802 Mil. Therefore, Bristol-Myers Squibb Co's EV-to-EBIT ratio for today is 13.86.
*** Please note that the current Enterprise Value is calculated using the current market capitalization and the most recently available financial data. If key financial fields—Long-Term Debt & Capital Lease Obligation and Short-Term Debt & Capital Lease Obligation—are recorded as null in the latest reporting period, our data vendor will default to using data from the prior period with valid entries.
Bristol-Myers Squibb Co (MIL:1BMY) Enterprise Value Explanation
When an investor buy a company, the investor needs to pay not only the common shares, he/she also needs to pay the shareholders of Preferred Stocks. He also assumes the debt of the company, and receives the cash on the company's balance sheet.
If a company has more cash than debt, the investor actually pays less than the Market Cap because he immediately owns the cash once the transaction goes through.
The market value of Preferred Stock needs to be added to the market value of common stocks in the calculation of Enterprise Value.
For the companies with the same Market Cap, the smaller the Enterprise Value is, the cheaper the company is.
Enterprise Value can be negative when the company's net cash is more than its Market Cap. In this case the investor is basically getting the company for free and get paid for that.
1. EV-to-EBIT is calculated as Enterprise Value divided by its EBIT.
Bristol-Myers Squibb Co's current Enterprise Value is €135,828 Mil.
Bristol-Myers Squibb Co's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €9,802 Mil.
2. EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA.
Bristol-Myers Squibb Co's EV-to-EBITDA for today is:
Bristol-Myers Squibb Co's current Enterprise Value is €135,828 Mil.
Bristol-Myers Squibb Co's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €12,888 Mil.
Bristol-Myers Squibb Co's current Enterprise Value is €135,828 Mil.
Bristol-Myers Squibb Co's Revenue for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €41,666 Mil.
Bristol-Myers Squibb Co's current Enterprise Value is €135,828 Mil.
Bristol-Myers Squibb Co's Cash Flow from Operations for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €11,414 Mil.
Bristol-Myers Squibb Co's current Enterprise Value is €135,828 Mil.
Bristol-Myers Squibb Co's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €10,212 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Bristol-Myers Squibb Co Enterprise Value Related Terms
Bristol-Myers Squibb Co Enterprise Value Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MIL:1BMY vs PFE, GILD, AMGN: Enterprise Value Comparison
For the Drug Manufacturers - General subindustry, Bristol-Myers Squibb Co's Enterprise Value, along with its competitors' market caps and Enterprise Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Bristol-Myers Squibb Co Enterprise Value vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Bristol-Myers Squibb Co's Enterprise Value distribution charts can be found below:
* The bar in red indicates where Bristol-Myers Squibb Co's Enterprise Value falls into.
Bristol-Myers Squibb Co Enterprise Value Calculation
Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
Bristol-Myers Squibb Co's Enterprise Value for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Enterprise Value of €135,828 Mil mean?
Bristol-Myers Squibb Co (MIL:1BMY) has a Enterprise Value of €135,828 Mil as of Jul. 03, 2026. Enterprise value equals the sum of market cap, debt and preferred shares less cash and equivalents. View historical data on Bristol-Myers Squibb Co and its competitors.
Is Bristol-Myers Squibb Co's Enterprise Value too high?
Bristol-Myers Squibb Co's current Enterprise Value is €135,828 Mil. Overall, Bristol-Myers Squibb Co has a GF Score™ of 49/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Bristol-Myers Squibb Co's Enterprise Value compare to PFE and GILD?
Bristol-Myers Squibb Co's Enterprise Value of €135,828 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Enterprise Value for a Drug Manufacturers company?
A good Enterprise Value depends on the Drug Manufacturers industry context. However, Enterprise Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Enterprise Value mean?
A high Enterprise Value can signal that a stock is expensive relative to its fundamentals. Enterprise value equals the sum of market cap, debt and preferred shares less cash and equivalents. View historical data on Bristol-Myers Squibb Co and its competitors. Bristol-Myers Squibb Co's current Enterprise Value is €135,828 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bristol-Myers Squibb Co stock overvalued right now?
Based on GuruFocus' analysis, Bristol-Myers Squibb Co (MIL:1BMY) is currently considered Fairly Valued. The stock's GF Value™ is €47.54, compared to a current price of €50.38 — trading 6% above its estimated fair value. The current Enterprise Value is €135,828 Mil. Bristol-Myers Squibb Co's overall GF Score™ is 49/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Enterprise Value calculated?
Enterprise Value is calculated from a company's financial statements. For Bristol-Myers Squibb Co (MIL:1BMY), the current Enterprise Value is €135,828 Mil as of Jul. 03, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Bristol-Myers Squibb Co (MIL:1BMY) Overvalued in 2026?
Based on GuruFocus' analysis, Bristol-Myers Squibb Co stock appears to be overvalued.
The current stock price of €50.38 is trading 6% above its estimated GF Value™ of €47.54.
GuruFocus considers Bristol-Myers Squibb Co to be Fairly Valued.
Key valuation signals for MIL:1BMY:
Enterprise Value: €135,828 Mil
GF Value™: €47.54 vs. price of €50.38 (6% above fair value)
No single metric tells the full story. See the MIL:1BMY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Bristol Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Bristol derives close to 70% of total sales from the US, showing a higher dependence on the US market than most of its peer group.
49GF Score
Get the complete analysis for MIL:1BMY
Enterprise Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MIL:1BMY has been successfully added to your 
